Regulus Therapeutics (RGLS) Stock Price, News & Analysis

Company Overview

Regulus Therapeutics, Inc. (NASDAQ:RGLS) is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics that target microRNAs, small non-coding RNA molecules known to regulate gene expression. Founded in 2007 as a joint venture between Alnylam Pharmaceuticals and Ionis Pharmaceuticals, Regulus has built a proprietary platform that enables the discovery and development of microRNA-targeted drugs. Headquartered in San Diego, California, the company’s research efforts focus on delivering innovative treatment options for diseases with significant unmet medical needs.

The company’s pipeline comprises several internally discovered and partnered programs across key therapeutic areas, including renal disease, metabolic disorders, and infectious diseases. Lead candidates such as RG-012, designed to inhibit microRNA-21 in patients with Alport syndrome, and RGLS8429, targeting microRNA-17 for the treatment of focal segmental glomerulosclerosis (FSGS), exemplify Regulus’s focus on precision molecular medicine. Additional pipeline assets investigate microRNA mechanisms in autosomal dominant polycystic kidney disease (ADPKD) and cardiometabolic indications, reflecting a diversified approach to microRNA modulation.

Regulus operates on a hybrid model of in-house research and strategic collaborations, leveraging partnerships to advance its microRNA platform. The company has forged alliances with leading pharmaceutical organizations and academic institutions to access complementary expertise and accelerate clinical development. These collaborations have expanded Regulus’s global reach, enabling it to conduct multi-regional clinical trials and facilitate regulatory interactions across North America, Europe, and Asia Pacific.

Under the leadership of President and Chief Executive Officer Jonathan H. Genzen, Regulus Therapeutics is guided by a team of industry veterans with extensive experience in RNA biology, drug development, and commercialization. The company’s board and scientific advisory panels include recognized experts in microRNA research and clinical development, supporting its mission to translate pioneering science into transformative therapies. Through its commitment to microRNA innovation, Regulus aspires to deliver novel treatment paradigms that address both rare and prevalent diseases worldwide.

Key Stats

• Today's Range: $8.16 to $8.16
• 50-Day Range: $3.37 to $8.30
• 52-Week Range: $0.83 to $8.35
• Volume: N/A
• Average Volume: 986,823 shs
• Market Capitalization: $564.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Hold

Regulus Therapeutics Stock Analysis - MarketRank™

Regulus Therapeutics scored higher than 32% of companies evaluated by MarketBeat, and ranked 750th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

Regulus Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 2 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Regulus Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Regulus Therapeutics are expected to decrease in the coming year, from ($0.88) to ($1.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Regulus Therapeutics is -11.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Regulus Therapeutics is -11.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Regulus Therapeutics has a P/B Ratio of 6.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.07% of the float of Regulus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Regulus Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Regulus Therapeutics has recently decreased by 15.79%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Regulus Therapeutics does not currently pay a dividend.

Dividend Growth

Regulus Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.07% of the float of Regulus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Regulus Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Regulus Therapeutics has recently decreased by 15.79%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 4 people have searched for RGLS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Regulus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Regulus Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $95,880.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 4.35% of the stock of Regulus Therapeutics is held by insiders.

Percentage Held by Institutions

92.38% of the stock of Regulus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RGLS Stock Analysis - Frequently Asked Questions

How have RGLS shares performed this year?

Regulus Therapeutics' stock was trading at $1.58 at the start of the year. Since then, RGLS stock has increased by 416.5% and is now trading at $8.16.

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc. (NASDAQ:RGLS) issued its quarterly earnings data on Thursday, May, 8th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.14.

When did Regulus Therapeutics' stock split?

Shares of Regulus Therapeutics reverse split on Wednesday, June 29th 2022.The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Regulus Therapeutics?

Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Regulus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Regulus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Eli Lilly and Company (LLY).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RGLS
• CIK: 1505512
• Web: www.regulusrx.com
• Phone: (858) 202-6300
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.50
• High Stock Price Target: $11.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +4.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$46.36 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -57.53%
• Return on Assets: -53.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.31
• Quick Ratio: 16.31

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.17 per share
• Price / Book: 6.97

Miscellaneous

• Outstanding Shares: 69,230,000
• Free Float: 66,222,000
• Market Cap: $564.92 million
• Optionable: Optionable
• Beta: 0.35